A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0724
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Rhein Sensitizes Human Pancreatic Cancer Cells to EGFR Inhibitors by Inhibiting STAT3 Pathway

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2019English

Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells With MEK/ERK Signaling Pathway Inhibitors

PLoS ONE
Multidisciplinary
2015English

CCL21/CCR7 Prevents Apoptosis via the ERK Pathway in Human Non-Small Cell Lung Cancer Cells

PLoS ONE
Multidisciplinary
2012English

A YWHAZ Variant Associated With Cardiofaciocutaneous Syndrome Activates the RAF-ERK Pathway

Frontiers in Physiology
Physiology
2019English

A Nuclear-Directed Human Pancreatic Ribonuclease (PE5) Targets the Metabolic Phenotype of Cancer Cells

Oncotarget
Oncology
2016English

P2.01-89 Synergistic Cytotoxicity Through MAPK/ERK Pathway and ALK Inhibition in Crizotinib Resistant EML4-ALK-Positive Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Using a Doe and Eis to Evaluate the Synergistic Effects of Low Toxicity Inhibitors for Mild Steel

Brazilian Journal of Chemical Engineering
Chemical Engineering
2015English

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

PLoS ONE
Multidisciplinary
2015English

APOL1 Variant-Expressing Endothelial Cells Exhibit Autophagic Dysfunction and Mitochondrial Stress

2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy